PHLPP Sensitizes Multiple Myeloma Cells to Bortezomib Through Regulating LAMP2

References

• Hu J, Hu WX. Targeting signaling pathways in multiple myeloma: pathogenesis and implication for treatments. Cancer Lett. 2018;414:214–221.29174802
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487–2498. doi:10.1056/NEJMoa04344515958804
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–766. doi:10.1056/NEJMoa160603827557302
   PubMed Web of Science ®Google Scholar
• Farrell ML, Reagan MR. Soluble and cell-cell-mediated drivers of proteasome inhibitor resistance in multiple myeloma. Front Endocrinol (Lausanne). 2018;9:218.29765356
   PubMed Web of Science ®Google Scholar
• Grzechnik AT, Newton AC. PHLPPing through history: a decade in the life of PHLPP phosphatases. Biochem Soc Trans. 2016;44(6):1675–1682. doi:10.1042/BST2016017027913677
   PubMedGoogle Scholar
• Newton AC, Trotman LC. Turning off AKT: PHLPP as a drug target. Annu Rev Pharmacol Toxicol. 2014;54:537–558.24392697
   PubMed Web of Science ®Google Scholar
• Lv D, Yang H, Wang W, et al. High PHLPP expression is associated with better prognosis in patients with resected lung adenocarcinoma. BMC Cancer. 2015;15:687.
   Google Scholar
• Wen YA, Stevens PD, Gasser ML, Andrei R, Gao T. Downregulation of PHLPP expression contributes to hypoxia-induced resistance to chemotherapy in colon cancer cells. Mol Cell Biol. 2013;33(22):4594–4605. doi:10.1128/MCB.00695-1324061475
   PubMed Web of Science ®Google Scholar
• Alessandrini F, Pezze L, Ciribilli Y. LAMPs: shedding light on cancer biology. Semin Oncol. 2017;44(4):239–253. doi:10.1053/j.seminoncol.2017.10.01329526252
   PubMed Web of Science ®Google Scholar
• Pajares M, Rojo AI, Arias E, et al. Transcription factor NFE2L2/NRF2 modulates chaperone-mediated autophagy through the regulation of LAMP2A. Autophagy. 2018;14(8):1310–1322. doi:10.1080/15548627.2018.147499229950142
   PubMed Web of Science ®Google Scholar
• Dubois A, Furstoss N, Calleja A, et al. LAMP2 expression dictates azacytidine response and prognosis in MDS/AML. Leukemia. 2019;33:1501–1513. doi:10.1038/s41375-018-0336-130607021
   PubMed Web of Science ®Google Scholar
• Gentile M, Recchia AG, Mazzone C, Morabito F. Emerging biological insights and novel treatment strategies in multiple myeloma. Expert Opin Emerg Drugs. 2012;17(3):407–438. doi:10.1517/14728214.2012.71334522920042
   PubMed Web of Science ®Google Scholar
• Fuchs O. Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma. Cardiovasc Hematol Disord Drug Targets. 2013;13(1):16–34. doi:10.2174/1871529X1131301000323534949
   PubMedGoogle Scholar
• Wang W, Hayashi J, Serrero G. PC cell-derived growth factor confers resistance to dexamethasone and promotes tumorigenesis in human multiple myeloma. Clin Cancer Res. 2006;12(1):49–56. doi:10.1158/1078-0432.CCR-05-092916397023
   PubMed Web of Science ®Google Scholar
• Tsuyama N, Ishikawa H, Abroun S, et al. The regulatory mechanism of IL-6-dependent proliferation of human myeloma cells. Hematology. 2003;8(6):409–411. doi:10.1080/1024533031000162130514668037
   PubMedGoogle Scholar
• Kuhn DJ, Berkova Z, Jones RJ, et al. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood. 2012;120(16):3260–3270. doi:10.1182/blood-2011-10-38678922932796
   PubMed Web of Science ®Google Scholar
• Xiang RF, Wang Y, Zhang N, et al. MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway. Cell Death Dis. 2017;8(5):e2776. doi:10.1038/cddis.2017.18828492559
   PubMedGoogle Scholar
• Pei H, Li L, Fridley BL, et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell. 2009;16(3):259–266. doi:10.1016/j.ccr.2009.07.01619732725
   PubMed Web of Science ®Google Scholar
• Nitsche C, Edderkaoui M, Moore RM, et al. The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation. Gastroenterology. 2012;142(2):377–387. doi:10.1053/j.gastro.2011.10.02622044669
   PubMed Web of Science ®Google Scholar
• Qu YQ, Gordillo-Martinez F, Law B, et al. 2-Aminoethoxydiphenylborane sensitizes anti-tumor effect of bortezomib via suppression of calcium-mediated autophagy. Cell Death Dis. 2018;9(3):361. doi:10.1038/s41419-018-0397-029500417
   PubMed Web of Science ®Google Scholar
• Arias E. Lysosomal mTORC2/PHLPP1/Akt axis: a new point of control of chaperone-mediated autophagy. Oncotarget. 2015;6(34):35147–35148. doi:10.18632/oncotarget.v6i3426436591
   PubMedGoogle Scholar
• Arias E, Koga H, Diaz A, et al. Lysosomal mTORC2/PHLPP1/Akt regulate chaperone-mediated autophagy. Mol Cell. 2015;59(2):270–284. doi:10.1016/j.molcel.2015.05.03026118642
   PubMed Web of Science ®Google Scholar
• Shang Z, Yu J, Sun L, et al. LncRNA PCAT1 activates AKT and NF-kappaB signaling in castration-resistant prostate cancer by regulating the PHLPP/FKBP51/IKKalpha complex. Nucleic Acids Res. 2019;47(8):4211–4225. doi:10.1093/nar/gkz10830773595
   PubMed Web of Science ®Google Scholar
• Tang B, Ma J, Ha X, Zhang Y, Xing Y. Tumor necrosis factor-alpha upregulated PHLPP1 through activating nuclear factor-kappa B during myocardial ischemia/reperfusion. Life Sci. 2018;207:355–363.29940243
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002;21(37):5673–5683. doi:10.1038/sj.onc.120566412173037
   PubMed Web of Science ®Google Scholar
• Bao L, Lv L, Feng J, et al. miR-487b-5p regulates temozolomide resistance of lung cancer cells through LAMP2-medicated autophagy. DNA Cell Biol. 2016;35(8):385–392. doi:10.1089/dna.2016.325927097129
   PubMed Web of Science ®Google Scholar
• Rowland TJ, Sweet ME, Mestroni L, Taylor MR. Danon disease - dysregulation of autophagy in a multisystem disorder with cardiomyopathy. J Cell Sci. 2016;129(11):2135–2143. doi:10.1242/jcs.18477027165304
   PubMed Web of Science ®Google Scholar
• Kallunki T, Olsen OD, Jaattela M. Cancer-associated lysosomal changes: friends or foes? Oncogene. 2013;32(16):1995–2004. doi:10.1038/onc.2012.29222777359
   PubMed Web of Science ®Google Scholar
• Piao S, Amaravadi RK. Targeting the lysosome in cancer. Ann N Y Acad Sci. 2016;1371(1):45–54. doi:10.1111/nyas.1295326599426
   PubMedGoogle Scholar